KKR & Co. Inc., a leading global investment firm, today announced that it has acquired a majority ownership stake in ...

KKR’s deal is a bet that financing needs from drug companies will continue to rise. - Michael Nagle/Bloomberg News. KKR has ...

Investment firm KKR (KKR) announced on Wednesday the acquisition of a majority stake in the biopharma royalty acquisition company, HealthCare Royalty Partners.

NEW YORK (Reuters) -Investment giant KKR reported a 9% rise in adjusted net income for the second quarter on Thursday, ...

KKR plows deeper into industry with HealthCare Royalty Partners investment; Why Vinay Prasad resigned from the FDA after less than three months; Indie scientific groups step into the gap for ...

Q2 2025 Earnings Call Transcript July 31, 2025 KKR & Co. Inc. beats earnings expectations. Reported EPS is $1.18, ...

KKR continues its aggressive transformation from traditional private equity into a diversified financial powerhouse through strategic acquisitions and fund initiatives. The investment giant recently ...

As part of the transaction, HCRx Chairman and CEO Clarke Futch will continue to lead the HCRx team and will maintain an ongoing substantial minority interest in HCRx.

Detailed price information for KKR & Company LP (KKR-N) from The Globe and Mail including charting and trades.

Q2 2025 Management View Co-CEO Scott C. Nuttall highlighted the company's strong performance, stating that fee-related earnings per share reached $0.98, total operating earnings were $1.33 per share, ...

The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the ...